Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey

INTRODUCTION: Were the participants of the EMPA-REG OUTCOME trial representative of patients receiving empagliflozin in clinical practice? The aim of the present study was to examine the prevalence of cardiovascular disease (CVD) in type 2 diabetes patients starting empagliflozin treatment in routin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes Ther
Hauptverfasser: Eliasson, Björn, Ekelund, Jan, Amberntsson, Rikard, Miftaraj, Mervete, Svensson, Ann-Marie
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Healthcare 2019
Schlagworte:
Brief Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612325/
https://ncbi.nlm.nih.gov/pubmed/31089969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0632-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge